Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE6.6700
- TODAY'S CHANGE (%)0.1200 (1.8321%)
- Bid / Lots6.0300/ 1
- Ask / Lots6.8500/ 19
- Open / Previous Close6.4700 / 6.5500
- Day Range
- 52 Week Range
- Volume74,325
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 2522 | 6.47 |
| 09:33 ET | 150 | 6.5 |
| 09:37 ET | 323 | 6.57 |
| 09:42 ET | 2917 | 6.68 |
| 09:46 ET | 100 | 6.7 |
| 09:48 ET | 978 | 6.68 |
| 10:00 ET | 200 | 6.74 |
| 10:02 ET | 400 | 6.69 |
| 10:08 ET | 653 | 6.65 |
| 10:24 ET | 100 | 6.65 |
| 10:29 ET | 135 | 6.61 |
| 10:33 ET | 520 | 6.615 |
| 10:38 ET | 500 | 6.57 |
| 10:42 ET | 1544 | 6.57 |
| 10:45 ET | 300 | 6.61 |
| 10:49 ET | 100 | 6.63 |
| 10:51 ET | 420 | 6.65 |
| 11:02 ET | 900 | 6.675 |
| 11:05 ET | 715 | 6.65 |
| 11:14 ET | 198 | 6.64 |
| 11:25 ET | 100 | 6.6 |
| 11:39 ET | 1214 | 6.62 |
| 11:41 ET | 286 | 6.63 |
| 11:45 ET | 2037 | 6.74 |
| 11:48 ET | 600 | 6.71 |
| 11:52 ET | 350 | 6.71 |
| 11:54 ET | 900 | 6.655 |
| 11:59 ET | 400 | 6.63 |
| 12:01 ET | 215 | 6.605 |
| 12:08 ET | 200 | 6.61 |
| 12:10 ET | 200 | 6.605 |
| 12:12 ET | 100 | 6.61 |
| 12:14 ET | 600 | 6.615 |
| 12:15 ET | 600 | 6.6 |
| 12:17 ET | 100 | 6.605 |
| 12:19 ET | 900 | 6.565 |
| 12:21 ET | 100 | 6.57 |
| 12:24 ET | 300 | 6.59 |
| 12:26 ET | 100 | 6.59 |
| 12:28 ET | 2217 | 6.604 |
| 12:30 ET | 800 | 6.61 |
| 12:32 ET | 200 | 6.605 |
| 12:33 ET | 400 | 6.615 |
| 12:35 ET | 100 | 6.62 |
| 12:37 ET | 417 | 6.61 |
| 12:46 ET | 1200 | 6.66 |
| 12:48 ET | 100 | 6.64 |
| 12:50 ET | 5664 | 6.65 |
| 12:51 ET | 300 | 6.65 |
| 12:55 ET | 900 | 6.63 |
| 12:57 ET | 693 | 6.625 |
| 01:00 ET | 17440 | 6.67 |
Nov 15, 2024
DJ Kodiak Sciences Is Maintained at Underweight by Barclays, from 10:01AM ET on Friday Nov 15, 2024 by Dow Jones
10:01AM ET on Friday Nov 15, 2024 by Dow JonesDJ Kodiak Sciences Price Target Maintained With a $3.00/Share by HC Wainwright & Co., from 6:31AM ET on Friday Nov 15, 2024 by Dow Jones
6:31AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
*DJ Kodiak Sciences 3Q Loss/Shr 84c >KOD, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow JonesKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 11, 2024
Kodiak Sciences to Participate in Upcoming Investor Conferences, from 6:15AM ET on Monday Nov 11, 2024 by Dow Jones
6:15AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 344.7M | -1.8x | --- |
Design Therapeutics Inc | 348.2M | -7.1x | --- |
Jasper Therapeutics Inc | 348.6M | -4.8x | --- |
Q32 Bio Inc | 327.9M | -3.6x | --- |
Northwest Biotherapeutics Inc | 324.5M | -4.5x | --- |
Compass Pathways PLC | 309.3M | -2.1x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $344.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.35 |
EPS | $-3.65 |
Book Value | $5.06 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
